Alterity Therapeutics Limited
ATH.AX
Australian Securities Exchange0.71
AUD
+0.04
- -
Alterity Therapeutics Limited
ATH.AX
(Australian Securities Exchange)
Recent
price
0.71
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Alterity Therapeutics Limited (ASX:ATH; NASDAQ:ATHE), a clinical-stage biotechnology company founded in 1997 and headquartered in Melbourne, Australia, with operations in the United States, develops disease-modifying therapies targeting neurodegenerative diseases including multiple system atrophy, Parkinson's disease, Alzheimer's disease, and Huntington's disease; its lead product candidate ATH434, an oral small molecule that inhibits alpha-synuclein aggregation and redistributes excess brain iron to reduce oxidative stress, has completed Phase 2 clinical trials in early-stage multiple system atrophy demonstrating positive topline results with robust clinical efficacy including a 48% treatment effect, FDA Fast Track and Orphan Drug designations, and ongoing open-label extension studies; the company also advances a preclinical pipeline of next-generation small molecules addressing protein misfolding pathology in Parkinsonian disorders. Alterity Therapeutics conducts global clinical trials across Australia, the United States, the United Kingdom, Italy, France, and Austria, and supports natural history studies like bioMUSE to validate imaging and biomarker endpoints for disease progression. In September 2025, the company raised A$20 million through a strategic placement to institutional investors led by a major international healthcare fund to advance ATH434's regulatory strategy with the FDA and pursue partnerships; recent milestones include FDA Fast Track Designation for ATH434 in May 2025, completion of last patient visits in Phase 2 trials ATH434-201 and ATH434-202 in December 2024 and March 2025 respectively, positive Phase 2 data announcements in January 2025, multiple data presentations at medical congresses including the International MSA Congress and American Academy of Neurology in 2025, appointment of Abby Macnish Niven as Chief Financial Officer in September 2024, and new publications on ATH434's neuroprotective mechanisms and composition-of-matter patents in Europe and the United States.